Home › NDC Lookup › Ingredients › Triamcinolone Acetonide Cream 0.1%, Tran... › 72835-0777-02
Dermavyx Triamcinolone Acetonide Cream 0.1%, Transparent Dressing Kit — NDC 72835-0777-02 package photo

Dermavyx Triamcinolone Acetonide Cream 0.1%, Transparent Dressing Kit

by V2 Pharma, LLC · 1 KIT in 1 CARTON (72835-777-02) * 1 TUBE in 1 CARTON (16714-986-03) / 80 g in 1 TUBE * 10 in 1 BOX
NDC 72835-0777-02
🏷️ FDA NDC (as labeled) 72835-777-02 billing pads the product segment with a zero
Rx only On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 72835-777-02
Product NDC 72835-777
11-digit billing NDC 72835077702
NCPDP billing unit EA — each (per item)
RxCUI 1014314
SPL Set ID 47cd01ec-6675-4c5f-b69b-8ec87afb6034
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-05-05
Dosage form KIT
GCN Seq No 089001
GCN 59235
HICL code 051352
Ingredient (HICL) Triamcinolone/Dressing
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 84:06.08.00
AHFS class Corticosteroids (Skin, Mucous Membrane)
FDB label name DERMAVYX 0.1% KIT
FDB brand name Dermavyx
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 72835-777-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 72835-0777-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerV2 Pharma, LLC
Labeler code72835
First marketedMay 2026
Product typeHuman Prescription Drug
Portfolio13 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name DERMAVYX 0.1% KIT Ingredient Triamcinolone/Dressing
📖 What it is MedlinePlus · NLM

Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Yes, intra-articular triamcinolone is specifically approved to give short-term relief for knee arthritis, gout flares, bursitis, and similar joint conditions. The extended-release...
  • I'm getting a triamcinolone injection in my knee. Will it actually help, and how long does it last?
  • That's a really important thing to flag with your doctor before your injection or prescription. Triamcinolone can raise blood sugar — even in people whose diabetes is well-controll...
  • I have diabetes. Should I be worried about using triamcinolone?
📖 Read our full Triamcinolone guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide 1 mg/g 45802-0064-05 Padagis 454 g $0.028 AT Availability likely —
triamcinolone acetonide 1 mg/g 00168-0004-15 E. 1 tube $0.100 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 00713-0225-15 Cosette 1 tube $0.100 AT Discontinued —
Triamcinolone Acetonide 1 mg/g 16714-0986-01 NorthStar 1 tube $0.100 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 21922-0062-04 Encube 1 tube $0.100 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 33342-0329-15 Macleods 1 tube $0.100 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 51672-1282-01 Sun 1 tube $0.100 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 67877-0251-15 Ascend 15 g $0.100 AT Availability likely —
Triamcinolone Acetonide 1 mg/g 71656-0042-15 Saptalis 1 tube $0.100 AT Availability likely —
Triderm 1 mg/g 00316-0170-01 Crown 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-0162-00 A-S 80 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-0228-00 A-S 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 50090-2106-00 A-S 30000 mg — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-6547-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 50090-6566-00 A-S 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 52817-0811-15 TruPharma, 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0234-30 Direct_Rx 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 61919-0650-15 DIRECTRX 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63187-0025-15 Proficient 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63187-0053-15 Proficient 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63187-0870-15 Proficient 1 tube — — FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8778-01 Bryant 15 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8779-01 Bryant 30 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8780-01 Bryant 80 g — AT FDA listed —
Triamcinolone acetonide 1 mg/g 63629-8781-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63629-9573-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 63629-9574-01 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 66267-0933-80 NuCare 80 g — — FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-2736-03 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3666-03 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3852-08 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-3982-05 NuCare 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4383-05 NuCare 15 g — — FDA listed —
triamcinolone acetonide 1 mg/g 68071-4391-03 NuCare 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68071-4945-05 NuCare 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68462-0131-17 Glenmark 1 tube — — FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-7797-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8350-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8356-00 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 68788-8753-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-1524-00 REMEDYREPACK 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2285-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2403-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 70518-2963-00 REMEDYREPACK 1 tube — AT Discontinued —
Triamcinolone Acetonide 1 mg/g 70518-4527-00 REMEDYREPACK 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71205-0627-15 Proficient 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 71335-2211-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71335-2712-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 71335-2713-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72162-1386-04 Bryant 1 tube — AT FDA listed —
Triamcinolone acetonide 1 mg/g 72162-1832-03 Bryant 30 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0039-80 Direct_Rx 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0277-15 Direct_Rx 15 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0330-80 Direct 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0571-80 Direct_rx 80 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 72189-0670-30 Direct_rx 30 g — AT FDA listed —
Dermavyxthis 72835-0777-02 V2 1 kit — — FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0203-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 76420-0348-00 Asclemed 454 g — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0071-30 Proficient 1 tube — AT FDA listed —
Triamcinolone Acetonide 1 mg/g 82804-0145-30 Proficient 1 tube — AT FDA listed —
Triadermex 84460-0100-08 Florrax 1 kit — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2026
On the market since
May 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
72835-0777-02 You're viewing this 1 KIT in 1 CARTON (72835-777-02) * 1 TUBE in 1 CARTON (16714-986-03) / 80 g in 1 TUBE * 10 in 1 BOX 2026-05-05 Active

🧭 About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application Kit / multi-component package

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

Kit / multi-component package

This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 72835-777-02, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 72835-0777-02, written without dashes as 72835077702. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 72835-0777-02, the first segment (72835) is the labeler code FDA assigned to V2 Pharma, LLC; the middle segment (0777) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (02) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by V2 Pharma, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
V2 Pharma, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage 36 words ▾

INDICATION AND USAGE Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

INDICATIONS & USAGE: Triamcinolone Acetonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 209 words ▾

DOSAGE & ADMINISTRATION: Apply Triamcinolone Acetonide Cream 0.025% to the affected area two to four times daily. Rub in gently. Apply the 0.1% or the 0.5% Triamcinolone Acetonide Cream, as appropriate, to the affected area two to three times daily.

Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears.

Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis.

It may be convenient to apply triamcinolone acetonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 60 words ▾

ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

🤰 Pregnancy 95 words ▾

Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 114 words ▾

Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 17 words ▾

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

🧬 Clinical Pharmacology 192 words ▾

CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 76 words ▾

HOW SUPPLIED: Triamcinolone Acetonide Cream USP, 0.1% 80 gram tube NDC 16714-986-03 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat. PROTECT FROM FREEZING.

Manufactured for: Northstar Rx LLC. Memphis, TN 38141. Manufactured by: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA To report SUSPECT ADVERSE REACTIONS, contact NorthStar Rx LLC 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

📋 Description 191 words ▾

DERMAVYX DESCRIPTION Dermavyx is supplied as 4 components in a kit : - 1 TUBE OF TRIAMCINOLONE ACETONIDE CREAM 0.1%, 80g - 30 SHEETS OF TRANSPARENT DRESSING (3 BOXES OF 10 SHEETS)

DESCRIPTION: The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis- (oxy)]-, (11β,16α)-], with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50.

CAS 76-25-5. The structural formula is: Triamcinolone Acetonide Cream USP, 0.025% contains: 0.25 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

Triamcinolone Acetonide Cream USP, 0.5% contains: 5 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. structure

💬 Information for Patients 127 words ▾

Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.

It is for dermatologic use only. Avoid contact with the eyes. 2.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.

Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 72835-0701-02 · V2 72835-0902-02 · V2 →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.